CoChat

Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Echinomycin is a novel bifunctional intercalating agent derived from Streptomyces echinatus. A phase II clinical trial of echinomycin in patients with advanced, measurable colorectal cancer was initiated to determine the efficacy and toxicities of this agent. Echinomycin, 1.5 mg/m2, was given initially as a 30- to 60-min infusion every 4 weeks. After 4 episodes of anaphylaxis had occurred among the first 14 patients, the schedule was changed to a 24-h infusion, and an additional 16 patients were treated on this schedule. Treatment was given every 3 weeks. A total of 30 patients were eligible and evaluable; there were 3 (10%; 90% confidence interval, 3%-23%) clinical responses lasting 3, 3+, and 12 months, respectively. The most serious toxicity encountered was anaphylaxis, which occurred in 5 patients, although with no serious sequelae. A premedication regimen with dexamethasone, diphenhydramine, and cimetidine and a change of the duration of the infusion to 24 h reduced the incidence of this complication. Grade 2-3 vomiting occurred among earlier patients treated; however, with the 24-h schedule this toxicity was substantially reduced. The sole important case of hematologic toxicity was a single patient with grade 3 thrombocytopenia. Echinomycin employed in this dose and schedule had modest activity against colorectal cancer, comparable with that observed with 5-fluorouracil. Further studies in patients with gastrointestinal malignancies using a 24-h infusion with a dexameth…

Overview

Integrity signals

Registry

Crossref · 10.1007/bf00685088

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

The citation lists are queued

They are fetched later and appear here then.

References 13 · Cited by 43

Research works printed but not linked: 2

  1. Leichman CG, Fleming TR, Muggia FM, Ardalan B, Doroshow J, Tangen C, Macdonald J (1993) Fluorouracil (5-FU) schedules and modulation in advanced colorectal cancer (CRC): a Southwest Oncology Group (SWOG) screening trial. Proc Am Soc Clin Oncol 12: 198
  2. National Cancer Institute (1988) Guidelines for reporting of adverse drug reactions. Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland

Metadata

Authors
Wadler, S., Tenteromano, L., Cazenave, L., Sparano, J. A., Greenwald, E. S., Rozenblit, A., Kaleya, R., & Wiernik, P. H.
Affiliations
  • Albert Einstein College of Medicine (US)
  • Montefiore Medical Center (US)
  • National Institutes of Health (US)
Venue
Cancer Chemotherapy and Pharmacology
Published
1994
Volume
34
Issue
3
Pages
266-269
ISSN
  • 0344-5704 (ISSN-L)
  • 1432-0843
OpenAlex
W2024990517
Cited by
43
References
13
Citations by year
2025: 1 · 2024: 2 · 2023: 5 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 1 · 2015: 3 · 2014: 4 · 2012: 2
FWCI
0.60
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Cancer Chemotherapy and Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
Keywords
echinomycin, colorectal cancer, anaphylaxis, infusion schedule, dexamethasone premedication, vomiting, thrombocytopenia, antitumor efficacy, 5-fluorouracil comparison
MeSH terms
Adenocarcinoma, Adult, Aged, Aged, 80 and over, Echinomycin, Female, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Colorectal Neoplasms, Survival Analysis, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. https://app.cochat.ai/papers/10.1007/bf00685088
The paper
Wadler, S., Tenteromano, L., Cazenave, L., Sparano, J. A., Greenwald, E. S., Rozenblit, A., Kaleya, R., & Wiernik, P. H. (1994). Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/bf00685088

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.